Martin Shkreli

1. THE FACT: The speaker states, "we bought a photonic/optical computing stock: $QCLS. i'm convinced that the answer to frontier computing is optical, not quantum. we're calling it 'quantum class' so investors understand it. $100 is my near-term target." 2. THE BRIDGE: The speaker has made a direct investment in QCLS, believes optical computing is the future of frontier computing over quantum, and has a specific, aggressive near-term price target of $100. This indicates strong conviction and a clear bullish outlook. 3. THE VERDICT: Long QCLS based on the speaker's conviction that optical computing is the future, their personal investment, and a near-term price target of $100.

Short CAPR; Shkreli explicitly labels the company a complete fraud, implying terminal structural impairment beyond valuation criticism, though no specific mechanism is stated and no personal short position is disclosed.

1. THE FACT: Martin Shkreli states that "quantum will continue to sink as $NVDA buys Groq, showing no interest in QC." He also states "the need for compute is still real. i think we have to think about a path past transistor-based computing, or we will actually cover the world (and space?) in data centers". 2. THE BRIDGE: NVDA's acquisition of Groq, a company focused on AI inference chips, indicates a strategic move to strengthen its position in the high-performance computing and AI sector, rather than quantum computing. This suggests NVDA is doubling down on a proven and growing market (AI/compute) where demand is "still real," while Shkreli believes quantum computing will "sink." 3. THE VERDICT: NVDA is making strategic acquisitions to solidify its leadership in the high-demand compute sector, specifically AI, which is a positive indicator for its continued growth.

Author is bullish on OABI, citing strong management, a recent LLY deal, and a highly valuable royalty on ramantamig.

Shkreli discloses he purchased LITE following its earnings print, correcting the parent's characterization of him as short AI/photonics names; low conviction due to rhetorical phrasing but reads as a genuine position disclosure.

Short CRWV — Shkreli argues the business is structurally trapped in perpetual re-levering: delevering would kill growth, so the company must keep tapping debt markets indefinitely, a model he explicitly frames as unsustainable using the Valeant analogy.

Short DOCS as a forced-seller catalyst (a pod shop blowing up) creates technical selling pressure, while the underlying quarter was uninspiring — offering a clean entry on the short side.

Short AAOI into the recent price pop; the revenue tailwind from a one-year supply bottleneck is temporary and does not reflect durable competitive advantage in what remains a commodity product business.

Buy GOOGL because the company's institutional scale transcends any individual leadership; engineer departures may pressure the board to demand management changes or strategic course corrections that unlock value.

Short HIMS on the basis that its peptide-based product lines (likely compounded GLP-1/semaglutide offerings) lack legitimate medical efficacy — author argues the core growth driver is scientifically unfounded, implying structural revenue risk if regulatory or clinical scrutiny intensifies.

Buy RDDT into the rumor-driven selloff linked to GOOGL; Shkreli expresses personal conviction at current levels and is conducting an expert call with a former RDDT executive, suggesting fundamental due diligence supports the bullish view.

Short CPHI as fair value is $0.10, implying extreme overvaluation and expected decline.

Short AGEN; a recent PIPE financing fails to alter the company's fundamentally weak outlook, and the stock should revert to the PIPE offering price, implying meaningful downside from current levels.

Short JLHL; Shkreli discloses an active short position, citing CEO Jiaqi Hu's control of BJIDE — a related party accounting for 53% of revenue — as a structural red flag consistent with a pump-and-dump scheme now in the dump phase.

Buy EVMN on the dip following a drug failure, as the overhang clears and market attention can now re-rate the IL-18 program, a potentially differentiated asset in the autoimmune space.